Artera and Tempus are collaborating to expand access to Artera’s AI-based prostate cancer test. Currently connected to more ...

Refusing to slow down since the start of the new year, shares of Tempus AI (NASDAQ: TEM) have skyrocketed nearly 99% since ...

Tempus AI (TEM) stock surged 13.4% on Thursday, hitting a new 52-week high of $86. The upside came after the health ...

Personalis shows promise in cancer detection but is years away from profitability. Read why PSNL stock is rated a hold with ...

Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care ...

Tempus AI (TEM) announced a new collaboration with the Institute for Follicular Lymphoma Innovation. The collaboration aims to develop and make ...

Regarding the transaction, the lawmaker disclosed on January 14 the accumulation of 50 call options in Tempus AI with a ...

Tempus AI shares were up 14% ... instability status and companion diagnostic claims for colorectal cancer patients, said the Chicago-based company.

Initially, Tempus AI's main initial focus has been on cancer research or oncology, where it has established business ties with roughly 2,500 institutions. According to its investor presentation ...

Tempus AI was one of them ... language models (LLM), a platform that it says is 50 times larger than The Cancer Genome Atlas (TCGA). This is just a momentum move in TEM stock unrelated to its ...

Imagene's AI-based multigene panel for predicting non-small cell lung cancer biomarkers from biopsy images will be combined with Tempus' real-world data.